Stockholm, April 4, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Isofol Medical AB’s shares (short name: ISOFOL) commenced today on Nasdaq First North Premier in Stockholm. Isofol Medical belongs to the health care sector and is the 21 st company to be admitted to trading on Nasdaq’s Nordic markets* in 2017.
Isofol Medical is a clinical stage pharmaceutical company headquartered in Gothenburg, Sweden. Its lead candidate, Modufolin, is a novel folate-based therapy developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin with access to the patented production process and the production capabilities of Merck KGaA in Darmstadt, Germany. For more information, please visit www.isofolmedical.se .
“I am pleased to say that the interest in Isofol has been very big, especially from knowledgeable investors in Sweden, Europe and the US,” said Anders Rabbe, CEO of Isofol Medical. “This means that we have secured the financing of the final pivotal study and that we can now focus on bringing Modufolin to the patients.”
“We welcome Isofol Medical to Nasdaq First North Premier,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “Isofol Medical joins our strong and growing health care sector, and we look forward to supporting the company for many years to come.”
Isofol Medical AB has appointed FNCA Sweden AB as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com .
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius .
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
| Media Relations Contact: Erik Granström +46 8 405 78 07 erik.granstrom@nasdaq.com |
